October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Midatech's MTX110 Receives Orphan Designation for DIPG Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering inn

("Midatech" or the "Company")

Midatech's MTX110 Receives Orphan Designation

PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products

to patients, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted the Company orphan

drug designation for MTX110 for the treatment of patients with Malignant Glioma, including Diffuse Intrinsic Pontine Glioma ("DIPG"),

a rare and fatal form of childhood brain cancer. MTX110 is a novel solubilised formulation of the HDAC-inhibitor panobinostat that

is currently being evaluated in an ongoing combined Phase 1 (safety) and Phase II (efficacy) programme in patients with DIPG.

for the treatment of childhood brain cancers such as DIPG, an ultra-rare highly aggressive and inoperable tumour located in the

brain stem, that is universally fatal with an average life expectancy of 7 to 9 months. Midatech is also evaluating MXT110 for

the treatment of other childhood brain cancers such as Medulloblastoma, and also Glioblastoma Multiforme ("GBM") which

is a fast-growing form of brain cancer in adults.

Craig Cook, CEO of Midatech said: "Receiving orphan drug designation for MTX110 is another important milestone to emerge

from our innovative MTX110 programme, based on our MidaSolve technology. We are pleased with the progress we are making in the

clinic at present and hope to ultimately demonstrate that MTX110 can serve as a safe and effective treatment option for these patients.

We look forward to providing further updates as the development programme progresses."

by the FDA is granted to support the development of drugs that target rare diseases with high unmet needs, affecting 200,000 or

fewer U.S. patients annually, and that are expected to provide significant therapeutic advantage over existing treatments. Orphan

designation qualifies a company for benefits that apply across all stages of drug development, including an accelerated approval

process, seven years of market exclusivity upon regulatory approval, if received, tax credits for qualified U.S. clinical trials,

eligibility for orphan drug grants, and exemption from certain administrative fees.

announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For more information, please contact:

for Concentrate for Solution for Infusion is a water-soluble form of panobinostat free base, achieved through complexation with

hydroxypropyl- -cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses

directly to the site of the tumor. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor

(pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (FarydakR) is not suitable for

treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. MTX110

takes the known active HDACi panobinostat (which is available in oral form only), and solubilises it into liquid form using Midatech's

MidaSolve technology. This increases available routes of administration for panobinostat and is essential because the drug does

not cross the blood-brain barrier effectively when given orally. MTX110 can therefore be delivered directly to a patient's tumour

via a catheter system (Convection Enhanced Delivery, or "CED"), infused into and around the tumour under pressure, thereby

bypassing the blood-brain barrier. This technique allows for high drug concentrations to be delivered to the tumour while simultaneously

minimising systemic toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in

vitro and in vivo models, and in a key study it was the most effective of 83 anticancer agents tested in several patient DIPG cell

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate

to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding

the potential treatment options for MTX110 and the development of the programme.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise